| B-06 Marjorie Imperial Stratified medicine approaches for drug susceptible tuberculosis patients Wednesday 11:15-11:35 |
| B-07 Stefanie Hennig Repeated time-to-event models support that Pseudomonas aeruginosa infection increase the risk of acquiring Aspergillus in young children with cystic fibrosis Wednesday 11:35-11:55 |
| B-08 María García-Cremades Individual level data meta-analysis from HIV pre-exposure prophylaxis (PrEP) clinical trials Wednesday 11:55-12:15 |
| B-11 Chiara Nicolò Machine learning combined to mechanistic modeling of differential effects of neoadjuvant sunitinib on primary tumor and metastatic growth Wednesday 14:30-14:50 |
| B-17 Zinnia Parra-Guillen Disease pharmacokinetic-pharmacodynamic (PKPD) modelling to support the development of gene therapy treatments for rare diseases Wednesday 17:25-17:45 |
| B-18 Pascal Chanu A disease progression model for geographic atrophy Wednesday 17:45-18:05 |
| C-08 Sylvie Retout A model-based extrapolation enabled labelling of emicizumab in haemophilia A paediatric patients <1 year old despite lack of clinical data Thursday 12:05-12:25 |
| D-02 Coralie Tardivon Association between tumor size kinetics and survival in advanced urothelial carcinoma patients treated with atezolizumab: implication for patient’s follow-up Friday 09:40-10:00 |
| D-03 Jiajie Yu A new approach to predict PFS in Ovarian Cancer based on tumor growth dynamics. Friday 10:00-10:20 |
| D-07 James Lu Integrated efficacy-safety QSP model of acute myeloid leukemia (AML) generates insights into the role of clinical dose schedules on cytopenia Friday 11:20-11:40 |
